Review




Structured Review

STEMCELL Technologies Inc serum-free expansion medium stemspan sfem
Serum Free Expansion Medium Stemspan Sfem, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspan+serum-free+expansion+medium+sfem/stemspan+serum+free+expansion+medium/pm40350476-208-9-14
Average 90 stars, based on 1 article reviews
serum-free expansion medium stemspan sfem - by Bioz Stars, 2026-10
90/100 stars

Images

Related Articles

other:

Article Title: Combination therapies for treating cancer
Article Snippet: Wild type mouse bone marrow cells were cultured in StemSpan Serum-Free Expansion Medium (SFEM, Stemcell Technologies), 100 U/ml Penicillin and 100 mg/ml Streptomycin (Life Technologies) supplemented with 6 ng/ml murine recombinant IL3, 10 ng/ml murine recombinant IL6, and 50 ng/ml murine recombinant SCF.

Article Title: Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells.
Article Snippet: HSPC barcoding, and barcode data analysis Rhesus CD34+ HSPCs were pre-stimulated for 16- 36 hours in HSPC culture medium StemSpan Serum-Free Expansion Medium (SFEM, STEMCELL Technologies) with 100 ng/ml of SCF, TPO and Flt3 at a cell concentration of 13106 cells/mL on RetroNectin (Takara, Bio) coated plates.

Article Title: Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia
Article Snippet: Primary AML blasts were incubated in StemSpan Serum-Free Expansion Medium (SFEM; Stemcell Technologies, Vancouver, BC, Canada) with recombinant human interleukin-6 (IL-6, PeproTech, Rocky Hill, NJ, USA), stem cell factor (SCF, PeproTech), and interleukin-3 (IL-3, PeproTech) at 10 ng/mL each.

Article Title: Synergistic effect and molecular mechanism of nicotinamide and UM171 in ex vivo expansion of long-term hematopoietic stem cells
Article Snippet: CD34+ cells were seeded at 5 × 10 4 /mL in serum-free medium, which was composed of StemSpan Serum-free Expansion Medium (SFEM, StemCell Technologies), supplemented with 10 ng/ml human stem cell factor (SCF, Miltenyi biotec), 100 ng/ml thrombopoietin (TPO, Miltenyi biotec), 1% Penicillin-Streptomycin-Glutamine (Gibco).

Article Title: Current status of red blood cell manufacturing in 3D culture and bioreactors.
Article Snippet: Briefly, HSCs are expanded using erythropoietin (EPO), stem cell factor (SCF), and interleukin-3 (IL-3) in a base medium; Iscove’s modified Dulbecco’s medium (IMDM) or StemSpan serum-free expansion medium (SFEM, Stem Cell Technologies, Vancouver, BC, Canada).

Article Title: Bioluminescence Imaging and ICP-MS Associated with SPION as a Tool for Hematopoietic Stem and Progenitor Cells Homing and Engraftment Evaluation.
Article Snippet: The bone epiphyses were removed and using a 1 mL syringe, the bone cavity was rinsed with StemSpan Serum-Free Expansion Medium (SFEM; Stem Cell Technologies, Vancouver, BC, Canada) supplemented with 100 U/mL of penicillin, 100 μg/mL of streptomycin, and 0.25 μg/mL of Gibco Amphotericin B (GIBCO—Invitrogen Technologies, New York, NY, USA).

Recombinant:

Article Title: Engineering Cell-Specific Protein Delivery Vehicles for Erythroid Lineage Cells
Article Snippet: HUDEP-2 cells (Riken RCB4557) were obtained from the Riken BioResource Research Center (Japan). .. In brief, cells were maintained in expansion medium, which contains StemSpan serum-free expansion medium (SFEM, Stemcell Technologies), 2% Penicillin-Streptomycin solution (10,000 U/mL stock), 50 ng/mL recombinant human stem cell factor (SCF, Stemcell Technologies), 3 IU/mL Epoetin alfa (Epogen, Amgen), 0.4 μg/mL dexamethasone, and 1 μg/mL doxycycline. .. Jurkat were maintained in RPMI 1640 (Gibco #11875093) with 10% heat-inactivated fetal bovine serum (FBS, #16140071) and 100 U/mL penicillin/streptomycin (Gibco #15140122).



Similar Products

90
STEMCELL Technologies Inc serum-free expansion medium stemspan sfem
Serum Free Expansion Medium Stemspan Sfem, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspan+serum-free+expansion+medium+sfem/stemspan+serum+free+expansion+medium/pm40350476-208-9-14
Average 90 stars, based on 1 article reviews
serum-free expansion medium stemspan sfem - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc stemspan serum-free expansion medium (sfem) ii
(A) Target genomic site within <t>the</t> <t>NHP</t> IGH locus, between the VDJ genes and the constant regions, sequence verified in two NHP species, M. mulatta and M. nemestrina . All possible Cas9 and Cas12a guides were screened within this sequence. (B) CD34 + <t>HSPC</t> were isolated from M. nemestrina bone marrow aspirates and electroporated with RNP. Target locus was analyzed for genetic edits, including single nucleotide polymorphisms (SNP), insertions, and deletions (indel). (C) CD34 + purity following immunomagnetic separation as measured by flow cytometry. (D, E) Indel frequency of selected Cas9 (D) and Cas12a (E) guides 3 days after electroporation of 10 CD34 + cells (n = 3 biological replicates, 3 donors). Data are presented as mean ± standard deviation (SD). Significance was calculated with an ordinary one-way ANOVA with *p<0.05, and **p<0.01.
Stemspan Serum Free Expansion Medium (Sfem) Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspan+serum-free+expansion+medium+sfem/stemspan+serum+free+expansion+medium/bio_rxiv__2025__05__02__651933-159-8-16
Average 90 stars, based on 1 article reviews
stemspan serum-free expansion medium (sfem) ii - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc stemspan serum-free expansion medium (sfem)
(A) Target genomic site within <t>the</t> <t>NHP</t> IGH locus, between the VDJ genes and the constant regions, sequence verified in two NHP species, M. mulatta and M. nemestrina . All possible Cas9 and Cas12a guides were screened within this sequence. (B) CD34 + <t>HSPC</t> were isolated from M. nemestrina bone marrow aspirates and electroporated with RNP. Target locus was analyzed for genetic edits, including single nucleotide polymorphisms (SNP), insertions, and deletions (indel). (C) CD34 + purity following immunomagnetic separation as measured by flow cytometry. (D, E) Indel frequency of selected Cas9 (D) and Cas12a (E) guides 3 days after electroporation of 10 CD34 + cells (n = 3 biological replicates, 3 donors). Data are presented as mean ± standard deviation (SD). Significance was calculated with an ordinary one-way ANOVA with *p<0.05, and **p<0.01.
Stemspan Serum Free Expansion Medium (Sfem), supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspan+serum-free+expansion+medium+sfem/stemspan+serum+free+expansion+medium/pmc12043090-247-12-17
Average 90 stars, based on 1 article reviews
stemspan serum-free expansion medium (sfem) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc stemspan serum-free expansion medium sfem
(A) Target genomic site within <t>the</t> <t>NHP</t> IGH locus, between the VDJ genes and the constant regions, sequence verified in two NHP species, M. mulatta and M. nemestrina . All possible Cas9 and Cas12a guides were screened within this sequence. (B) CD34 + <t>HSPC</t> were isolated from M. nemestrina bone marrow aspirates and electroporated with RNP. Target locus was analyzed for genetic edits, including single nucleotide polymorphisms (SNP), insertions, and deletions (indel). (C) CD34 + purity following immunomagnetic separation as measured by flow cytometry. (D, E) Indel frequency of selected Cas9 (D) and Cas12a (E) guides 3 days after electroporation of 10 CD34 + cells (n = 3 biological replicates, 3 donors). Data are presented as mean ± standard deviation (SD). Significance was calculated with an ordinary one-way ANOVA with *p<0.05, and **p<0.01.
Stemspan Serum Free Expansion Medium Sfem, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspan+serum-free+expansion+medium+sfem/stemspan+serum+free+expansion+medium/pmc12006860-87-10-15
Average 90 stars, based on 1 article reviews
stemspan serum-free expansion medium sfem - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc stemspan serum-free expansion medium ii (sfem ii)
(A) Target genomic site within <t>the</t> <t>NHP</t> IGH locus, between the VDJ genes and the constant regions, sequence verified in two NHP species, M. mulatta and M. nemestrina . All possible Cas9 and Cas12a guides were screened within this sequence. (B) CD34 + <t>HSPC</t> were isolated from M. nemestrina bone marrow aspirates and electroporated with RNP. Target locus was analyzed for genetic edits, including single nucleotide polymorphisms (SNP), insertions, and deletions (indel). (C) CD34 + purity following immunomagnetic separation as measured by flow cytometry. (D, E) Indel frequency of selected Cas9 (D) and Cas12a (E) guides 3 days after electroporation of 10 CD34 + cells (n = 3 biological replicates, 3 donors). Data are presented as mean ± standard deviation (SD). Significance was calculated with an ordinary one-way ANOVA with *p<0.05, and **p<0.01.
Stemspan Serum Free Expansion Medium Ii (Sfem Ii), supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspan+serum-free+expansion+medium+sfem/stemspan+serum+free+expansion+medium/pm39928955-58-8-15
Average 90 stars, based on 1 article reviews
stemspan serum-free expansion medium ii (sfem ii) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc stemspan serum free expansion medium (sfem) (09650)
(A) Target genomic site within <t>the</t> <t>NHP</t> IGH locus, between the VDJ genes and the constant regions, sequence verified in two NHP species, M. mulatta and M. nemestrina . All possible Cas9 and Cas12a guides were screened within this sequence. (B) CD34 + <t>HSPC</t> were isolated from M. nemestrina bone marrow aspirates and electroporated with RNP. Target locus was analyzed for genetic edits, including single nucleotide polymorphisms (SNP), insertions, and deletions (indel). (C) CD34 + purity following immunomagnetic separation as measured by flow cytometry. (D, E) Indel frequency of selected Cas9 (D) and Cas12a (E) guides 3 days after electroporation of 10 CD34 + cells (n = 3 biological replicates, 3 donors). Data are presented as mean ± standard deviation (SD). Significance was calculated with an ordinary one-way ANOVA with *p<0.05, and **p<0.01.
Stemspan Serum Free Expansion Medium (Sfem) (09650), supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspan+serum-free+expansion+medium+sfem/stemspan+serum+free+expansion+medium/pmc11960508-207-5-12
Average 90 stars, based on 1 article reviews
stemspan serum free expansion medium (sfem) (09650) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
StemCells Inc stemspan serum-free expansion medium (sfem)
(A) Target genomic site within <t>the</t> <t>NHP</t> IGH locus, between the VDJ genes and the constant regions, sequence verified in two NHP species, M. mulatta and M. nemestrina . All possible Cas9 and Cas12a guides were screened within this sequence. (B) CD34 + <t>HSPC</t> were isolated from M. nemestrina bone marrow aspirates and electroporated with RNP. Target locus was analyzed for genetic edits, including single nucleotide polymorphisms (SNP), insertions, and deletions (indel). (C) CD34 + purity following immunomagnetic separation as measured by flow cytometry. (D, E) Indel frequency of selected Cas9 (D) and Cas12a (E) guides 3 days after electroporation of 10 CD34 + cells (n = 3 biological replicates, 3 donors). Data are presented as mean ± standard deviation (SD). Significance was calculated with an ordinary one-way ANOVA with *p<0.05, and **p<0.01.
Stemspan Serum Free Expansion Medium (Sfem), supplied by StemCells Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspan+serum-free+expansion+medium+sfem/stemspan+serum+free+expansion+medium++sfem+/10__1039_slash_d4lp00207e-142-14-19
Average 90 stars, based on 1 article reviews
stemspan serum-free expansion medium (sfem) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


(A) Target genomic site within the NHP IGH locus, between the VDJ genes and the constant regions, sequence verified in two NHP species, M. mulatta and M. nemestrina . All possible Cas9 and Cas12a guides were screened within this sequence. (B) CD34 + HSPC were isolated from M. nemestrina bone marrow aspirates and electroporated with RNP. Target locus was analyzed for genetic edits, including single nucleotide polymorphisms (SNP), insertions, and deletions (indel). (C) CD34 + purity following immunomagnetic separation as measured by flow cytometry. (D, E) Indel frequency of selected Cas9 (D) and Cas12a (E) guides 3 days after electroporation of 10 CD34 + cells (n = 3 biological replicates, 3 donors). Data are presented as mean ± standard deviation (SD). Significance was calculated with an ordinary one-way ANOVA with *p<0.05, and **p<0.01.

Journal: bioRxiv

Article Title: In vivo production of an anti-HIV antibody from primate hematopoietic cells by non-viral knock-in

doi: 10.1101/2025.05.02.651933

Figure Lengend Snippet: (A) Target genomic site within the NHP IGH locus, between the VDJ genes and the constant regions, sequence verified in two NHP species, M. mulatta and M. nemestrina . All possible Cas9 and Cas12a guides were screened within this sequence. (B) CD34 + HSPC were isolated from M. nemestrina bone marrow aspirates and electroporated with RNP. Target locus was analyzed for genetic edits, including single nucleotide polymorphisms (SNP), insertions, and deletions (indel). (C) CD34 + purity following immunomagnetic separation as measured by flow cytometry. (D, E) Indel frequency of selected Cas9 (D) and Cas12a (E) guides 3 days after electroporation of 10 CD34 + cells (n = 3 biological replicates, 3 donors). Data are presented as mean ± standard deviation (SD). Significance was calculated with an ordinary one-way ANOVA with *p<0.05, and **p<0.01.

Article Snippet: Immediately following isolation, NHP HSPC were transferred to HSPC medium (StemSpan Serum-Free Expansion Medium (SFEM) II (StemCell Technologies) with 100 ng/mL recombinant human thrombopoietin (TPO), stem cell factor (SCF), and flightless 3 (FLT-3) ligand, all from CellGenix) at 1.0×10 cells/mL in tissue culture (TC)-treated flasks, incubated at 37°C and 5% CO 2 .

Techniques: Sequencing, Isolation, Immunomagnetic Separation, Flow Cytometry, Electroporation, Standard Deviation

(A) NHP HSPC electroporated with VH4-GFP Cas12a were injected into sub-lethally irradiated, neonatal MISTRG mice. Hematopoietic lineages in the primatized mice were monitored over time and at necropsy. (B) Engraftment levels in peripheral blood over time as measured by flow cytometry on NHP-CD45 + cells from mice injected with electroporated or control HSPC. n = 8 mice, n = 2 NHP donors (electroporated group, 1.39 × 10 CD34 + cells/mouse). n = 6 mice, n = 2 NHP donors (control group, 1.71 × 10 CD34 + cells/mouse). (C, D) Multilineage engraftment in peripheral blood over time as measured by frequency of B cells (CD3 - CD20 + ), T cells (CD3 + CD20 - ), and monocytes (CD3 - CD20 - CD14 + ) in NHP-derived populations (NHP-CD45 + ). (E) Engraftment levels in the bone marrow (femur) and the liver at necropsy, performed at week 20. Error bars represent SD. (F) In vivo transgene expression as measured by frequency of GFP + cells in NHP-derived populations (NHP-CD45 + ), as compared to total B cell frequency in peripheral blood over time. (G) Editing levels at the NHP IGH locus in peripheral blood as measured by high-throughput sequencing on MiSeq platform. Large insertions represented by insertions >8 bp. Lines represent means in (B, C, D, F, and G). n = 8 mice, n = 2 NHP donors (electroporated group, week 18 omitted for low engraftment levels, C-G).

Journal: bioRxiv

Article Title: In vivo production of an anti-HIV antibody from primate hematopoietic cells by non-viral knock-in

doi: 10.1101/2025.05.02.651933

Figure Lengend Snippet: (A) NHP HSPC electroporated with VH4-GFP Cas12a were injected into sub-lethally irradiated, neonatal MISTRG mice. Hematopoietic lineages in the primatized mice were monitored over time and at necropsy. (B) Engraftment levels in peripheral blood over time as measured by flow cytometry on NHP-CD45 + cells from mice injected with electroporated or control HSPC. n = 8 mice, n = 2 NHP donors (electroporated group, 1.39 × 10 CD34 + cells/mouse). n = 6 mice, n = 2 NHP donors (control group, 1.71 × 10 CD34 + cells/mouse). (C, D) Multilineage engraftment in peripheral blood over time as measured by frequency of B cells (CD3 - CD20 + ), T cells (CD3 + CD20 - ), and monocytes (CD3 - CD20 - CD14 + ) in NHP-derived populations (NHP-CD45 + ). (E) Engraftment levels in the bone marrow (femur) and the liver at necropsy, performed at week 20. Error bars represent SD. (F) In vivo transgene expression as measured by frequency of GFP + cells in NHP-derived populations (NHP-CD45 + ), as compared to total B cell frequency in peripheral blood over time. (G) Editing levels at the NHP IGH locus in peripheral blood as measured by high-throughput sequencing on MiSeq platform. Large insertions represented by insertions >8 bp. Lines represent means in (B, C, D, F, and G). n = 8 mice, n = 2 NHP donors (electroporated group, week 18 omitted for low engraftment levels, C-G).

Article Snippet: Immediately following isolation, NHP HSPC were transferred to HSPC medium (StemSpan Serum-Free Expansion Medium (SFEM) II (StemCell Technologies) with 100 ng/mL recombinant human thrombopoietin (TPO), stem cell factor (SCF), and flightless 3 (FLT-3) ligand, all from CellGenix) at 1.0×10 cells/mL in tissue culture (TC)-treated flasks, incubated at 37°C and 5% CO 2 .

Techniques: Injection, Irradiation, Flow Cytometry, Control, Derivative Assay, In Vivo, Expressing, Next-Generation Sequencing

(A) bnAb template was designed for expressing the full light chain and the variable heavy chain fragment of 10-1074. Following productive knock-in at the target locus, bnAb expression replaces endogenous antibody production, bypassing VDJ recombination and forming a full-length transcript via splicing with a constant heavy chain. (B) In vitro 10-1074 production as confirmed by staining of cell surface transgene linker. Flow cytometry was performed on HEK 293E cells following transduction with an expression vector containing an IgG constant heavy chain. (C) Binding of recombinant bnAb to HIV antigen, the gp120 protein of strain CN97001, as measured by bio-layer interferometry (BLI) and quantified as the dissociation constant (K D ). n = 6 technical replicates. (D) NHP HSPC were electroporated with VH4-10-1074 Cas12a , either as dsDNA or AAV, and transplanted into MISTRG mice as before. Beginning at week 8, mice were immunized with CN97001 gp120 injections once every two weeks until necropsy. Control mice were injected with unedited HSPC. (E) Engraftment levels in peripheral blood over time as measured by flow cytometry on NHP-CD45 + cells in mice injected with edited HSPC using different templates. (F) In vivo anti-HIV antibody titers were measured by ELISA with a biotinylated gp120 on diluted plasma samples. dsDNA: n = 5 mice, n = 2 NHP donors. AAV: n = 2 mice, n = 2 NHP donors. Control: n = 1 mouse, n = 2 NHP donors. n = 2 technical replicates per sample. (G) Cell surface expression of 10-1074 in peripheral blood as measured by flow cytometry with antibody against its linker. (H) Editing levels at the NHP IGH locus in peripheral blood as measured by high-throughput sequencing (MiSeq). Large insertions represent insertions >8 bp. (I) B cell populations and fraction of B cell population expressing 10-1074 at necropsy, week 18, as measured by flow cytometry on NHP-CD19 + . n = 5 mice, n = 2 NHP donors (10-1074 dsDNA group, G-J). Error bars represent SD.

Journal: bioRxiv

Article Title: In vivo production of an anti-HIV antibody from primate hematopoietic cells by non-viral knock-in

doi: 10.1101/2025.05.02.651933

Figure Lengend Snippet: (A) bnAb template was designed for expressing the full light chain and the variable heavy chain fragment of 10-1074. Following productive knock-in at the target locus, bnAb expression replaces endogenous antibody production, bypassing VDJ recombination and forming a full-length transcript via splicing with a constant heavy chain. (B) In vitro 10-1074 production as confirmed by staining of cell surface transgene linker. Flow cytometry was performed on HEK 293E cells following transduction with an expression vector containing an IgG constant heavy chain. (C) Binding of recombinant bnAb to HIV antigen, the gp120 protein of strain CN97001, as measured by bio-layer interferometry (BLI) and quantified as the dissociation constant (K D ). n = 6 technical replicates. (D) NHP HSPC were electroporated with VH4-10-1074 Cas12a , either as dsDNA or AAV, and transplanted into MISTRG mice as before. Beginning at week 8, mice were immunized with CN97001 gp120 injections once every two weeks until necropsy. Control mice were injected with unedited HSPC. (E) Engraftment levels in peripheral blood over time as measured by flow cytometry on NHP-CD45 + cells in mice injected with edited HSPC using different templates. (F) In vivo anti-HIV antibody titers were measured by ELISA with a biotinylated gp120 on diluted plasma samples. dsDNA: n = 5 mice, n = 2 NHP donors. AAV: n = 2 mice, n = 2 NHP donors. Control: n = 1 mouse, n = 2 NHP donors. n = 2 technical replicates per sample. (G) Cell surface expression of 10-1074 in peripheral blood as measured by flow cytometry with antibody against its linker. (H) Editing levels at the NHP IGH locus in peripheral blood as measured by high-throughput sequencing (MiSeq). Large insertions represent insertions >8 bp. (I) B cell populations and fraction of B cell population expressing 10-1074 at necropsy, week 18, as measured by flow cytometry on NHP-CD19 + . n = 5 mice, n = 2 NHP donors (10-1074 dsDNA group, G-J). Error bars represent SD.

Article Snippet: Immediately following isolation, NHP HSPC were transferred to HSPC medium (StemSpan Serum-Free Expansion Medium (SFEM) II (StemCell Technologies) with 100 ng/mL recombinant human thrombopoietin (TPO), stem cell factor (SCF), and flightless 3 (FLT-3) ligand, all from CellGenix) at 1.0×10 cells/mL in tissue culture (TC)-treated flasks, incubated at 37°C and 5% CO 2 .

Techniques: Expressing, Knock-In, In Vitro, Staining, Flow Cytometry, Transduction, Plasmid Preparation, Binding Assay, Recombinant, Control, Injection, In Vivo, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Next-Generation Sequencing

(A) MISTRG6 mice were xenotransplanted using the same protocol applied in MISTRG mice, this time allowing up to 72 hours from birth for HSPC injections. Necropsy was performed at an earlier timepoint to allow the detection of 10-1074-producing cells while antibody titers were still detectable. Control mice received unedited CD34 + cells. (B) NHP engraftment levels in the peripheral blood of MISTRG6 mice over time. (C) B cells (NHP-CD4 - /CD8a - /CD20 + ) as a fraction of NHP lineage in the peripheral blood of MISTRG6 mice. (D) Anti-HIV antibody titers in the plasma of MISTRG6 mice as measured by ELISA. (E-G) 10-1074-expressing cells (Strep Tag II + ), IgG-producing cells (NHP-IgG + /CD138 + ), and plasma cells (NHP-CD20 -/low /CD31 + /CD138 + ) in different tissues of MISTRG6 mice at necropsy. (H) Fraction of total 10-1074-expressing cells found across all tissues that are either B cells, antibody-producing cells, or plasma cells. (I) Editing levels at the target locus in peripheral blood. n = 8 mice, n = 3 NHP donors. Error bars represent SD. Red lines in (B-C) represent immunizations.

Journal: bioRxiv

Article Title: In vivo production of an anti-HIV antibody from primate hematopoietic cells by non-viral knock-in

doi: 10.1101/2025.05.02.651933

Figure Lengend Snippet: (A) MISTRG6 mice were xenotransplanted using the same protocol applied in MISTRG mice, this time allowing up to 72 hours from birth for HSPC injections. Necropsy was performed at an earlier timepoint to allow the detection of 10-1074-producing cells while antibody titers were still detectable. Control mice received unedited CD34 + cells. (B) NHP engraftment levels in the peripheral blood of MISTRG6 mice over time. (C) B cells (NHP-CD4 - /CD8a - /CD20 + ) as a fraction of NHP lineage in the peripheral blood of MISTRG6 mice. (D) Anti-HIV antibody titers in the plasma of MISTRG6 mice as measured by ELISA. (E-G) 10-1074-expressing cells (Strep Tag II + ), IgG-producing cells (NHP-IgG + /CD138 + ), and plasma cells (NHP-CD20 -/low /CD31 + /CD138 + ) in different tissues of MISTRG6 mice at necropsy. (H) Fraction of total 10-1074-expressing cells found across all tissues that are either B cells, antibody-producing cells, or plasma cells. (I) Editing levels at the target locus in peripheral blood. n = 8 mice, n = 3 NHP donors. Error bars represent SD. Red lines in (B-C) represent immunizations.

Article Snippet: Immediately following isolation, NHP HSPC were transferred to HSPC medium (StemSpan Serum-Free Expansion Medium (SFEM) II (StemCell Technologies) with 100 ng/mL recombinant human thrombopoietin (TPO), stem cell factor (SCF), and flightless 3 (FLT-3) ligand, all from CellGenix) at 1.0×10 cells/mL in tissue culture (TC)-treated flasks, incubated at 37°C and 5% CO 2 .

Techniques: Control, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Expressing, Strep-tag